Search

Your search keyword '"Schuler, M"' showing total 2,272 results

Search Constraints

Start Over You searched for: Author "Schuler, M" Remove constraint Author: "Schuler, M"
2,272 results on '"Schuler, M"'

Search Results

3. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

5. Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity

8. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study

22. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

24. MA21.09 More Accurate Staging of Stage IV Lung Cancer Through EUS B of the Left Adrenal Gland

25. MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

31. First Clinical Experience with Gallium-68-OPS-202 PET for Imaging SCLC

32. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

33. Maligne Hodentumoren

35. Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting.

40. A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma

42. EP04.02-007 First Comprehensive Lung Cancer Long-Term Survivorship Program- Competing Risks

43. Prognostic factors after pneumonectomy in lung cancer

45. Präoperative Immun-Checkpoint-Inhibitor-Therapie bei Frühstadien des nicht-kleinzelligem Lungenkrebs: NEOpredict-Lung – eine randomisierte, multizentrische Phase-II-Studie

47. EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival

49. MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC

50. 76P Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

Catalog

Books, media, physical & digital resources